FDA
-
-
-
-
-
-
-
Kiniksa reports 62% growth in ARCALYST revenue to $677.5 million
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Provides Corporate Update
-
-
-
-
-
-
-
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
-
-
-
-
-
-
-
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
-
327,852 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

